Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to announce ... organizations who need document translations. Clients will now have ... in advance with a selection of nearly 50 life science ... critical factor in clinical and scientific fields, and decrease the ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, has ... an emerging biomedical company acquiring, developing, manufacturing, and marketing ... Free report download: http://equitiesiq.com/reports/alliqua/ , In late ... and Board, which launched the company’s new strategy to ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... 20 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... China, notified,its shareholders today that the Annual ... 2007, has been postponed due the geographical,nature ... the mailing of,proxy materials. The Company is ...
... EDMONTON, Aug. 20 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), announced,today that it is ... bid,which will be conducted pursuant to the rules ... purchase up to 1,000,000 of its Class A ...
... ABUJA, August 20 The Chrome Group today announced ... of its companies on trading,platforms in Europe and the ... Group Chief Communications Officer, Mr. Val Oji said that ... Group was,implementing over the next two years. Chrome recently ...
Cached Biology Technology:Sinovac Announces Postponement of Annual General Meeting 2BioMS Medical announces its intention to renew a normal course issuer bid 2Chrome Group to Seek Listing for Some of its Subsidiaries 2Chrome Group to Seek Listing for Some of its Subsidiaries 3Chrome Group to Seek Listing for Some of its Subsidiaries 4
(Date:4/21/2014)... can help treat and prevent influenza and respiratory ... the lungs and breathing passages, according to research ... new Institute for Biomedical Sciences. , In a ... upcoming publication of the International Journal of Molecular ... ginseng, a well-known herbal medicine, on human health. ...
(Date:4/21/2014)... Like a daily pill to lower cholesterol can reduce ... reduces eye inflammation could help save the vision of ... already targeted with high doses of niacin to decrease ... also be an effective mark for these patients, said ... Georgia at Georgia Regents University. , Martin is ...
(Date:4/21/2014)... domesticated chili pepper now the world,s most ... team of researchers, led by a plant scientist ... from the four-pronged investigation based on linguistic ... traditional archaeological and genetic data suggest a ... the domesticated chili pepper. That region, extending from ...
Breaking Biology News(10 mins):Ginseng can treat and prevent influenza and RSV, researcher finds 2Scientists target receptor to treat diabetic retinopathy 2Scientists target receptor to treat diabetic retinopathy 3Birthplace of the domesticated chili pepper identified in Mexico 2
... Copenhagen, Herlev Hospital and Rigshospitalet have identified a clear link ... blood. In the long term, the research may well help ... been published in the Journal of the American College ... which the opening of the aortic valve is narrowed ...
... PULLMAN, Wash. A class of drugs used to treat ... treating cancers and immune-related diseases, a new WSU-led study has ... have a major impact on its ability to affect specific ... "This was rather unexpected, given how relatively simple the molecules ...
... iPhone users now have access to a free ... including electricity, natural gas, biodiesel, e85 Ethanol, propane ... Energy Laboratory (NREL) developed the new mobile application ... local stakeholders across the country in an effort ...
Cached Biology News:Danish researchers predict risk of valvular heart disease 2Researcher finds potential new use for old drugs 2NREL developed mobile app for alternative fueling station locations released 2
... Immunogen: Synthetic peptide derived from the C ... protein This peptide sequence is downstream ... Zymed polyclonal Connexin 36 antibody Cat. No. ... 36. Reactivity: Mouse (positive control: mouse ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
...
...
Biology Products: